Éric Legouffe
- Hematology top 1%
- Multiple Myeloma Research and Treatments 12
- Oncology top 2%
- Cancer Treatment and Pharmacology 6
- Genetics top 2%
- Chronic Lymphocytic Leukemia Research 6
- Cancer Research top 5%
- Cancer Genomics and Diagnostics 5
- Immunology top 5%
- Immunotherapy and Immune Responses 6
-
- Renal cell carcinoma treatment 7
-
- Lymphoma Diagnosis and Treatment 7
-
- PI3K/AKT/mTOR signaling in cancer 6
- Co-authors
- Bernard KleinKarin TarteÉric JourdanJérôme MoreauxThierry RèmeJean‐François RossiJean François RossiJohn De Vos
- Cited by
- HematologyOncologyGenetics
- Partner nations
- FranceSwitzerlandUnited Kingdom
In The Last Decade
Éric Legouffe
49 papers receiving 3.1k citations
Hit Papers
Peers
Comparison fields: 5 of 92
- Hematology 1.1k
- Oncology 1.3k
- Genetics 468
- Cancer Research 518
- Immunology 707
Countries citing papers authored by Éric Legouffe
This map shows the geographic impact of Éric Legouffe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Éric Legouffe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Éric Legouffe more than expected).
Fields of papers citing papers by Éric Legouffe
This network shows the impact of papers produced by Éric Legouffe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Éric Legouffe. The network helps show where Éric Legouffe may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Éric Legouffe, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 4 | |
| 2 | 2022 | 3 | |
| 3 | 2021 | 5 | |
| 4 | 2015 | 109 | |
| 5 | 2014 | 68 | |
| 6 | Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Studybreakdown → | 2012 | 539 |
| 7 | 2012 | 5 | |
| 8 | 2011 | 172 | |
| 9 | 2006 | 10 | |
| 10 | 2006 | 191 | |
| 11 | 2005 | 44 | |
| 12 | 2004 | 48 | |
| 13 | 2003 | 175 | |
| 14 | 2002 | 189 | |
| 15 | 2001 | 31 | |
| 16 | 1998 | 106 | |
| 17 | 1998 | 8 | |
| 18 | 1998 | 101 | |
| 19 | 1995 | 12 | |
| 20 | 1995 | 14 |
About Éric Legouffe
Éric Legouffe is a scholar working on Hematology, Genetics and Oncology, having authored 49 papers that have together received 3.2k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (12 papers), Renal cell carcinoma treatment (7 papers), Lymphoma Diagnosis and Treatment (7 papers), Chronic Lymphocytic Leukemia Research (6 papers), PI3K/AKT/mTOR signaling in cancer (6 papers), Immunotherapy and Immune Responses (6 papers), Cancer Treatment and Pharmacology (6 papers) and Cancer Genomics and Diagnostics (5 papers). The work is most often cited by research in Hematology (1.1k citations), Oncology (1.3k citations) and Genetics (468 citations). Éric Legouffe has collaborated with scholars based in France, Switzerland and United Kingdom. Frequent co-authors include Bernard Klein, Karin Tarte, Éric Jourdan, Jérôme Moreaux, Thierry Rème, Jean‐François Rossi, Jean François Rossi, John De Vos, Philippe Quittet and Claire Cropet. Their work appears in journals such as Blood, Journal of Clinical Oncology, Annals of Oncology, Bone Marrow Transplantation and Journal of the American Academy of Dermatology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.